MYRA GUITREAU-IEM: Open Payments
NPI 1821773953 · FREDERICKSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,231 in 110 payments from 10 companies in 2025. Trend: 2023 $497 · 2024 $1,829 · 2025 $2,231
Food & beverage: $2,226Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $473 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $328 |
| Vanda Pharmaceuticals Inc. | 15 | $312 |
| Neurocrine BioSciences, Inc. | 12 | $284 |
| Janssen Pharmaceuticals, Inc | 10 | $270 |
| ABBVIE INC. | 11 | $197 |
| Otsuka America Pharmaceutical, Inc. | 8 | $144 |
| Lundbeck LLC | 5 | $137 |
| E.R. Squibb & Sons, L.L.C. | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
Products named: ARISTADA, CAPLYTA, INGREZZA, INVEGA SUSTENNA, FANAPT, ABILIFY ASIMTUFII, VRAYLAR, HETLIOZ.
Industry payments across VA — which companies pay providers there.
